Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Low Cost Method Examines Single Leukemic Cells

By LabMedica International staff writers
Posted on 28 Oct 2016
Leukemia is a disease in which each cell can exhibit different genetic traits, and a cheap way has been developed to examine the individual cells and this breakthrough could transform leukemia treatment.

Cells are packed with genetic information that can be used to improve treatment of diseases such as cancer, but the ribonucleic acid (RNA) sequencing methods typically used today have one limitation in that they do not identify in which cells the genetic activity is taking place.

Scientists at the KTH Royal Institute of Technology (Stockholm, Sweden) and their colleagues developed a new method they used to examine individual tumor cells in patients with chronic lymphocytic leukemia (CLL), an important advance considering the team found the leukemia tumors to be comprised of cells with entirely different gene expressions. More...
They used cryopreserved peripheral blood mononuclear samples derived from three CLL patients. All cases were diagnosed and classified according to recently revised iwCLL criteria44 with a typical CLL immunophenotype.

Individual cells were sorted on a specially made glass surface and using analysis of RNA molecules with next-generation sequencing, from which one can tell which genes are active. The spatial information on the glass surface tells which cell a specific RNA molecule is to be found in. The FACS sorter utilized for analyses and single-cell sorting was a BD Influx. Images of sorted and stained cells on barcoded microarrays were recorded using a Metafer Vslide scanning system installed on an Axio Imager Z2 LSM700 microscope.

The method enabled massive microarray-based barcoding of expression patterns in single cells, termed MASC-seq. This technology enabled both imaging and high-throughput single-cell analysis, characterizing thousands of single-cell transcriptomes per day at a low cost of USD 0.13/cell, which is two orders of magnitude less than commercially available systems. The novel approach provides data in a rapid and simple way. Therefore, MASC-seq has the potential to accelerate the study of subtle clonal dynamics and help provide critical insights into disease development and other biological processes.

Joakim Lundeberg, PhD, a professor of Gene Technology and senior author of the study, said, “We found that CLL cells do not consist of a single cell type, but of a number of sub-clones that exhibit entirely different gene expression. With this new, highly cost-effective technology, we can now get a whole new view of this complexity within the blood cancer sample. Molecular resolution of single cells is likely to become a more widely-used therapy option.” The study was published on October 14, 2016, in the journal Nature Communications.

Related Links:
KTH Royal Institute of Technology


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.